HK-PFR-688_evaluation_survey

Skip to the content

Feedback survey
Thank you for your participation in the iBRCAf Pfizer symposium: Optimising mBC therapy in the era of PARP inhibitors. We hope that you found it useful. Your feedback is very important to us; we would appreciate it if you could complete this brief survey.

1. Please tell us what you think of the scientific content presented during the symposium (check all that apply): *

It was up to date and informative
It will be useful for my clinical practice
It has enhanced my interest in the subject area

2. Which aspect of the symposium did you find most useful? *

Discussion of clinical trial data
Discussion of real-world experience and cases
Q&A

3. The symposium has increased my knowledge/confidence in the use of PARP inhibitors when managing metastatic breast cancer. *

Strongly agree
Agree
Neutral
Disagree
Strongly disagree

4. Please rate your overall experience of the symposium: *

Excellent
Very good
Good
Fair
Poor

mBC, metastatic breast cancer; PARP, Poly (ADP-ribose) polymerase.

Pfizer Pte Ltd
80 Pasir Panjang Road, #16-81/82
Mapletree Business City, Singapore 117372
Tel: +65-6403 8888 Fax: +65-6403 8868 Website: www.pfizer.com.sg
Intended for Healthcare Professionals only

PP-TAL-SGP-0041/29JUL2022